Major pharmaceutical companies continually research and develop new cancer medications and treatments, which must be shown to be safe and effective before doctors can prescribe them to patients. Through cancer clinical trials, researchers test the effects of new drugs on a group of volunteers with cancer. Following a strict protocol and using carefully controlled conditions, researchers evaluate the drugs under development and measure the ability of the new drug to treat cancer, its safety, and any possible side effects.
Some patients with cancer are reluctant to take part in clinical trials for fear of getting no treatment at all for their cancer. This is simply not true. Patients with cancer who participate in cancer clinical trials receive the most effective therapy currently available for their cancer -- or they may receive cancer treatments that are being evaluated for future use. These cancer treatments may be even more effective than the current cancer treatment. The only way to determine if the newer treatment is better than the currently available treatment is by clinical trial participation.
There are several types of plasma cell neoplasms. These diseases are all associated with a monoclonal (or myeloma) protein (M protein). They include monoclonal gammopathy of undetermined significance (MGUS), isolated plasmacytoma of the bone, extramedullary plasmacytoma, and multiple myeloma.
(Refer to the Lymphoplasmacytic Lymphoma (Waldenström Macroglobulinemia) section in the PDQ summary on Adult Non-Hodgkin Lymphoma Treatment for more information.)
Incidence and Mortality
This web site, developed by the nonprofit Coalition of Cancer Cooperative Groups, is an unbiased cancer clinical trial matching and navigation service enabling patients to search for cancer trials based on disease and location.